{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T21:18:27Z","timestamp":1762809507256,"version":"3.41.2"},"reference-count":185,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443193507"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apcsb.2023.12.001","type":"book-chapter","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T08:49:20Z","timestamp":1704358160000},"page":"157-198","source":"Crossref","is-referenced-by-count":3,"title":["Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discovery"},{"issue":"10254","key":"10.1016\/bs.apcsb.2023.12.001_bib2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/1873-3468.14270","article-title":"CAR-Ts: New perspectives in cancer therapy","volume":"596","author":"Abrantes","year":"2022","journal-title":"FEBS Letters"},{"issue":"7774","key":"10.1016\/bs.apcsb.2023.12.001_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.001_bib5","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.001_bib6","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1038\/s41375-018-0285-8","article-title":"CAR T-cells for T-cell malignancies: Challenges in distinguishing between therapeutic, normal, and neoplastic T-cells","volume":"32","author":"Alcantara","year":"2018","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib7","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfusion"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Communication and Signaling"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250039","article-title":"Four challenges to CAR T cells breaking the glass ceiling","author":"Bailey","year":"2023","journal-title":"European Journal of Immunology"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.001_bib11","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3390\/cancers14112667","article-title":"Systematic review of available CAR-T cell trials around the world","volume":"14","author":"Barros","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib13","doi-asserted-by":"crossref","unstructured":"Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., & Whitlow, M. (1988). Single-chain antigen-binding proteins. Science, 242 (4877).","DOI":"10.1126\/science.3140379"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","author":"Bonifant","year":"2016","journal-title":"Molecular Therapy \u2013 Oncolytics"},{"issue":"13 Suppl.","key":"10.1016\/bs.apcsb.2023.12.001_bib15","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy","volume":"27","author":"Borgert","year":"2021","journal-title":"The American Journal of Managed Care"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nature Reviews Immunology"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib17","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","article-title":"Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes","volume":"181","author":"Brocker","year":"1995","journal-title":"The Journal of Experimental Medicine"},{"issue":"26","key":"10.1016\/bs.apcsb.2023.12.001_bib18","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"22","key":"10.1016\/bs.apcsb.2023.12.001_bib19","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.001_bib20","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1177\/1060028015588555","article-title":"Blinatumomab: A first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia","volume":"49","author":"Buie","year":"2015","journal-title":"The Annals of Pharmacotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-2824","article-title":"A high molecular weight melanoma-associated antigen \u2013 Specific chimeric antigen receptor redirects lymphocytes to target human melanomas","author":"Burns","year":"2010","journal-title":"Cancer Research"},{"issue":"32","key":"10.1016\/bs.apcsb.2023.12.001_bib22","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib23","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminoncol.2014.08.005","article-title":"From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies","author":"Caruana","year":"2014","journal-title":"Seminars in Oncology"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2020.00129","article-title":"Structural perspectives on extracellular recognition and conformational changes of several type-I transmembrane receptors","volume":"7","author":"Chataigner","year":"2020","journal-title":"Frontiers in Molecular Biosciences"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.001_bib27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: Property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib28","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib29","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00262-012-1202-z","article-title":"CAR T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer","volume":"61","author":"Chmielewski","year":"2012","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"NOV","key":"10.1016\/bs.apcsb.2023.12.001_bib31","article-title":"Antigen-specific T-cell activation independently of the MHC: Chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunological Reviews"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","author":"Chong","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"14","key":"10.1016\/bs.apcsb.2023.12.001_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147652","article-title":"Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment","volume":"22","author":"Cosenza","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104222","article-title":"Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression","author":"De Paula Pohl","year":"2020","journal-title":"Cellular Immunology"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.001_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2021.06.012","article-title":"The role of exhaustion in CAR T cell therapy","volume":"39","author":"Delgoffe","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26914","article-title":"Hypogammaglobulinemia due to CAR T-cell therapy","volume":"65","author":"Doan","year":"2018","journal-title":"Pediatric Blood & Cancer"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunological Reviews"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3390\/cancers15030567","article-title":"Non-conventional allogeneic anti-BCMA chimeric antigen receptor-based immune cell therapies for multiple myeloma treatment","volume":"15","author":"Du","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fimmu.2021.609421","article-title":"The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory\/recurrent multiple myeloma","volume":"12","author":"Duan","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib43","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","article-title":"Lymphocytes in cellular therapy: Functional regulation of CAR T cells","volume":"10","author":"Dwivedi","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib44","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7643","key":"10.1016\/bs.apcsb.2023.12.001_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib46","article-title":"Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy","volume":"158","author":"Ferrer-Curriu","year":"2023","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.001_bib47","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s11864-022-01035-2","article-title":"Evaluating the patient with neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"23","author":"Fortin Ensign","year":"2022","journal-title":"Current Treatment Options in Oncology"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/08923970903420582","article-title":"Lentiviral vectors for immune cells targeting","volume":"32","author":"Froelich","year":"2010","journal-title":"Immunopharmacology and Immunotoxicology"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/cpim.94","article-title":"Purification of T-cell populations","volume":"128","author":"Fuss","year":"2020","journal-title":"Current Protocols in Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.001_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/cgt.2014.71","article-title":"Manufacturing genetically modified T cells for clinical trials","volume":"22","author":"Gee","year":"2015","journal-title":"Cancer Gene Therapy 2015"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2023.12.001_bib53","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1182\/blood-2022-168456","article-title":"Lymphodepleting chemotherapy before CD19 directed CAR T-cell therapy: Are 3 days necessary?","volume":"140","author":"Geer","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","author":"Gross","year":"1989","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib56","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","author":"Grupp","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib57","first-page":"1","article-title":"IL13R\u03b12-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy","author":"Gu","year":"2023","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","article-title":"Engineering and design of chimeric antigen receptors","volume":"12","author":"Guedan","year":"2019","journal-title":"Molecular Therapy \u2013 Methods & Clinical Development"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/01.cji.0000161397.96582.59","article-title":"The role of extracellular spacer regions in the optimal design of chimeric immune receptors: Evaluation of four different scFvs and antigens","author":"Guest","year":"2005","journal-title":"Journal of Immunotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-023-01042-z","article-title":"Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: A systematic review and meta-analysis","author":"Guo","year":"2023","journal-title":"Clinical and Experimental Medicine"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.001_bib61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainresbull.2023.02.014","article-title":"CAR T-cells to treat brain tumors","author":"Guzman","year":"2023","journal-title":"Brain Research Bulletin"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib63","article-title":"Cardiotoxicity associated with chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies: A systematic review","volume":"14","author":"Hanna","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib64","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Experimental Hematology & Oncology"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.001_bib65","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014Challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Molecular Medicine"},{"issue":"21","key":"10.1016\/bs.apcsb.2023.12.001_bib66","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114609","article-title":"Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer","volume":"162","author":"He","year":"2023","journal-title":"Biomedicine and Pharmacotherapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib68","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib69","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T\u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Reviews"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib71","first-page":"169","article-title":"Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy","volume":"32","author":"Hollyman","year":"2009","journal-title":"Journal of Immunotherapy (Hagerstown, Md.: 1997)"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.001_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.001_bib74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nature Reviews Drug Discovery 2021"},{"issue":"19","key":"10.1016\/bs.apcsb.2023.12.001_bib75","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib76","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","author":"Hudecek","year":"2013","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib77","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-14-0127","article-title":"The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity","author":"Hudecek","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib78","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1016\/j.bbmt.2019.12.331","article-title":"Successful implementation of a chimeric antigen receptor T-cell risk evaluation and mitigation strategies (REMS) program","volume":"26","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","author":"Imai","year":"2004","journal-title":"Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U. K"},{"issue":"19\u201320","key":"10.1016\/bs.apcsb.2023.12.001_bib80","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the right tool for genetic engineering: Clinical lessons from chimeric antigen receptor-T cells","volume":"32","author":"Irving","year":"2021","journal-title":"Human Gene Therapy"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2023.12.001_bib81","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1182\/blood-2022-166082","article-title":"Phase I trial of humanized CD19 CART-cell therapy developed in India: Safe, active and feasible for outpatient therapy","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib82","article-title":"Perfusion\u2019s role in maintenance of high-density T-cell cultures","author":"Janas","year":"2015","journal-title":"BioProcess International"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: Elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib84","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","article-title":"CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities","volume":"25","author":"Kankeu Fonkoua","year":"2022","journal-title":"Molecular Therapy Oncolytics"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2023.12.001_bib86","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1182\/blood-2022-168928","article-title":"Making anti-CD19 CAR-T cell therapy accessible and affordable: First-in-human phase I clinical trial experience from India","volume":"140","author":"Karulkar","year":"2022","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib87","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.311.311","article-title":"Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture T cells expressing CD19-specific chimeric antigen receptor","author":"Kebriaei","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib88","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ejh.14076","article-title":"CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?","volume":"112","author":"Khan","year":"2024","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.001_bib89","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/protein\/gzu043","article-title":"Design and characterization of structured protein linkers with differing flexibilities","volume":"27","author":"Klein","year":"2014","journal-title":"Protein Engineering, Design and Selection"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/cco-22-125","article-title":"The emerging role for CAR T cells in solid tumor oncology","volume":"12","author":"Klobuch","year":"2023","journal-title":"Chinese Clinical Oncology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib91","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006059","article-title":"Diabetes insipidus and Guillain-Barr\u00e9-like syndrome following CAR-T cell therapy: A case report","volume":"11","author":"Koch","year":"2023","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/S1389-0344(01)00090-9","article-title":"Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting","author":"Kortt","year":"2001","journal-title":"Biomolecular Engineering"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.01.012","article-title":"Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: A multi-institution experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-022-03442-3","article-title":"Exhaustion of CAR T cells: Potential causes and solutions","volume":"20","author":"Kouro","year":"2022","journal-title":"Journal of Translational Medicine"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtct.2022.10.004","article-title":"Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus","volume":"29","author":"Kretschmann","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib96","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries on the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nature Reviews. Cancer"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib97","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell\u2010induced severe or life\u2010threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"The Oncologist"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib98","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib99","doi-asserted-by":"crossref","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells","author":"Levine","year":"2015","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib100","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR T cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Molecular Therapy \u2013 Methods & Clinical Development"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib101","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/19420862.2015.1111497","article-title":"Influence of molecular size on tissue distribution of antibody fragments","volume":"8","author":"Li","year":"2016","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib102","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"European Journal of Immunology"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib103","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib161","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/biomedicines10051012","article-title":"Tumor Lysis Syndrome: An Endless Challenge in Onco-Nephrology","volume":"10","author":"Lupus\u00b8oru","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib104","first-page":"1704","article-title":"A novel siglec-4 derived spacer improves the functionality of CAR T cells against membrane-proximal epitopes","volume":"1","author":"Maccalli","year":"2020","journal-title":"Frontiers in Immunology|www.frontiersin.org"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.001_bib105","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib106","doi-asserted-by":"crossref","unstructured":"Magnani, C. F., Tettamanti, S., Alberti, G., Pisani, I., Biondi, A., Serafini, M., & Gaipa, G. (n.d.). Transposon-based CAR T cells in acute leukemias: Where are we going? \u3008https:\/\/doi.org\/10.3390\/cells9061337\u3009.","DOI":"10.3390\/cells9061337"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.001_bib107","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from car t-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: Challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Research & Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.001_bib110","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.apsb.2020.12.015","article-title":"Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects","volume":"11","author":"Masoumi","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib111","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","author":"Maude","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib112","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","author":"Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib113","doi-asserted-by":"crossref","unstructured":"Mccomb, S., Nguyen, T., Shepherd, A., Henry, K. A., Bloemberg, D., Marcil, A. Weeratna, R. D. (n.d.). Antigenic sensitivity of membrane-proximal targeting chimeric antigen receptors can be fine-tuned through hinge truncation. \u3008https:\/\/doi.org\/10.1101\/2020.10.30.360925\u3009.","DOI":"10.1101\/2020.10.30.360925"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: A scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib115","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Molecular Therapy. Methods & Clinical Development"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.001_bib116","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib117","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib118","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/17474086.2016.1183479","article-title":"Medical management of side effects related to CAR T cell therapy in hematologic malignancies","volume":"9","author":"Namuduri","year":"2016","journal-title":"Expert Review of Hematology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib119","first-page":"68","article-title":"The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies","volume":"2","author":"Neal","year":"2017","journal-title":"Journal of Immunology Research and Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib120","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"15","key":"10.1016\/bs.apcsb.2023.12.001_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: Pathophysiology, clinical implications, and echocardiographic assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib122","doi-asserted-by":"crossref","unstructured":"Newick, K., O\u2019Brien, S., Moon, E., & Albelda, S. M. (2017). CAR T cell therapy for solid tumors, 68, 139\u2013152. https:\/\/doi.org\/10.1146\/ANNUREV-MED-062315-120245.","DOI":"10.1146\/annurev-med-062315-120245"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib123","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nature Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00262-004-0560-6","article-title":"A listing of human tumor antigens recognized by T cells: March 2004 update","volume":"54","author":"Novellino","year":"2005","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41417-021-00307-7","article-title":"TCR-like CARs and TCR-CARs targeting neoepitopes: An emerging potential","volume":"28","author":"Poorebrahim","year":"2021","journal-title":"Cancer Gene Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","author":"Pul\u00e8","year":"2005","journal-title":"Molecular Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib127","article-title":"An analysis of cardiac disorders associated with chimeric antigen receptor T cell therapy in 126 patients: A single-centre retrospective study","author":"Qi","year":"2021","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.001_bib129","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcyt.2015.05.013","article-title":"Low-cost generation of Good Manufacturing Practice\u2013grade CD19-specific chimeric antigen receptor\u2013expressing T cells using piggyBac gene transfer and patient-derived materials","volume":"17","author":"Ramanayake","year":"2015","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib130","doi-asserted-by":"crossref","first-page":"165.e1","DOI":"10.1016\/j.jtct.2022.12.020","article-title":"Apoptosis of hematopoietic stem cells contributes to bone marrow suppression following chimeric antigen receptor T cell therapy","volume":"29","author":"Read","year":"2023","journal-title":"Transplantation and Cellular Therapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/978-3-030-94353-0_27","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022","journal-title":"The EBMT\/EHA CAR-T Cell Handbook"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib132","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-1759(90)90210-M","article-title":"The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells","volume":"128","author":"Riddell","year":"1990","journal-title":"Journal of Immunological Methods"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.001_bib133","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Rita","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib134","unstructured":"Roccaro, A. M., Ashihara, E., Du, Z., Zhu, S., Zhang, X., Gong, Z., & Wang, S. (2023). Non-conventional allogeneic anti-BCMA chimeric antigen receptor-based immune cell therapies for multiple myeloma."},{"key":"10.1016\/bs.apcsb.2023.12.001_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167513","article-title":"Site-specific dinitrophenylation of single-chain antibody fragments for redirecting a universal CAR-T cell against cancer antigens","author":"Rong","year":"2022","journal-title":"Journal of Molecular Biology"},{"issue":"6576","key":"10.1016\/bs.apcsb.2023.12.001_bib136","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science (New York, N. Y.)"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2023.12.001_bib137","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jim.2010.11.007","article-title":"Large-scale bioreactor expansion of tumor-infiltrating lymphocytes","volume":"364","author":"Sadeghi","year":"2011","journal-title":"Journal of Immunological Methods"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib138","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor (CAR) design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discovery"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib139","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/21645515.2019.1571893","article-title":"CRISPR\/Cas9-based genome editing in the era of CAR T cell immunotherapy","volume":"15","author":"Salas-Mckee","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"Suppl. 3","key":"10.1016\/bs.apcsb.2023.12.001_bib140","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1186\/ar567","article-title":"The instructive role of dendritic cells on T-cell responses","volume":"4","author":"Sallusto","year":"2002","journal-title":"Arthritis Research"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib141","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/jcmm.17653","article-title":"Modifying enzyme replacement therapy \u2013 A perspective","volume":"27","author":"Schaible","year":"2023","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"Suppl. 1","key":"10.1016\/bs.apcsb.2023.12.001_bib142","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2019-125423","article-title":"Third-generation CAR T cells targeting CD19 are associated with an excellent safety profile and might improve persistence of CAR T cells in treated patients","volume":"134","author":"Schubert","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib143","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib144","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib145","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MDNA3-0030-2014","article-title":"Everyman\u2019s guide to bacterial insertion sequences","volume":"3","author":"Siguier","year":"2015","journal-title":"Microbiology Spectrum"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064138","article-title":"Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells","volume":"8","author":"Singh","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib147","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/cgt.2014.69","article-title":"Manufacture of T cells using the sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor","volume":"22","author":"Singh","year":"2015","journal-title":"Cancer Gene Therapy"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib148","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-69","article-title":"Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE\u00ae bioreactor","volume":"10","author":"Somerville","year":"2012","journal-title":"Journal of Translational Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib149","first-page":"1","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer Journal 2021"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib150","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"24","key":"10.1016\/bs.apcsb.2023.12.001_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20246223","article-title":"Optimizing manufacturing protocols of chimeric antigen receptor t cells for improved anticancer immunotherapy","volume":"20","author":"Stock","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib152","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6616391","article-title":"T cell exhaustion and CAR-T immunotherapy in hematological malignancies","volume":"2021","author":"Tang","year":"2021","journal-title":"BioMed Research International"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.001_bib153","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib154","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-030-94353-0_28","article-title":"Management of hypogammaglobulinaemia and B-cell aplasia","author":"Topp","year":"2022","journal-title":"The EBMT\/EHA CAR-T Cell Handbook"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"1\u20132","key":"10.1016\/bs.apcsb.2023.12.001_bib156","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0022-1759(03)00010-3","article-title":"T cell stimulation and expansion using anti-CD3\/CD28 beads","volume":"275","author":"Trickett","year":"2003","journal-title":"Journal of Immunological Methods"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.001_bib157","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2013.06.003","article-title":"Simplified process for the production of anti-CD19-CAR engineered T cells","volume":"15","author":"Tumaini","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib158","first-page":"61","article-title":"Tumor antigens","author":"Valilou","year":"2019","journal-title":"Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib159","series-title":"Encyclopedia of gastroenterology","first-page":"472","article-title":"Systemic lupus erythematosus","author":"Van Hagen","year":"2023"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.001_bib160","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism following BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib162","doi-asserted-by":"crossref","unstructured":"Verreycken, J., Baeten, P., & Broux, B. (2022). Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers. \u3008https:\/\/doi.org\/10.1080\/21645515.2022.2153534\u3009.","DOI":"10.1080\/21645515.2022.2153534"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib163","article-title":"Production and application of CAR T cells: Current and future role of Europe","volume":"1","author":"Volk","year":"2021","journal-title":"Frontiers in Medicine|www.frontiersin.org"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib164","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Current Opinion in Biotechnology"},{"issue":"14","key":"10.1016\/bs.apcsb.2023.12.001_bib165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.001_bib166","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3390\/antib8030043","article-title":"Design and production of bispecific antibodies","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.001_bib167","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.molonc.2015.10.019","article-title":"Intracellular antigens as targets for antibody based immunotherapy of malignant diseases","volume":"9","author":"Wang","year":"2015","journal-title":"Molecular Oncology"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.001_bib168","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jca.20302","article-title":"Conventional apheresis therapies: A review","volume":"26","author":"Ward","year":"2011","journal-title":"Journal of Clinical Apheresis"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.001_bib169","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1253656","article-title":"Fine-tuning the CAR spacer improves T-cell potency","volume":"5","author":"Watanabe","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib170","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/6.8.989","article-title":"An improved linker for single-chain fv with reduced aggregation and enhanced proteolytic stability","author":"Whitlow","year":"1993","journal-title":"Protein Engineering, Design and Selection"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib171","doi-asserted-by":"crossref","DOI":"10.1093\/protein\/7.8.1017","article-title":"Multivalent fvs: Characterization of single-chain Fv oligomers and preparation of a bispecific Fv","author":"Whitlow","year":"1994","journal-title":"Protein Engineering, Design and Selection"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib172","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor","author":"Wilkie","year":"2008","journal-title":"The Journal of Immunology"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.001_bib173","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5603\/OCP.2019.0016","article-title":"A novel immunotherapy\u2014The history of CAR T-cell therapy","volume":"15","author":"Wrona","year":"2019","journal-title":"Oncology in Clinical Practice"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib174","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","article-title":"Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells","volume":"17","author":"Wu","year":"2020","journal-title":"Cellular and Molecular Immunology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib175","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215699","article-title":"Therapeutic bispecific antibodies against intracellular tumor antigens","volume":"538","author":"Xu","year":"2022","journal-title":"Cancer Letters"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib177","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: Current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib178","first-page":"3402","article-title":"Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms","volume":"52","author":"Yokota","year":"1992","journal-title":"Cancer Research"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.001_bib179","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bi-specific chimeric antigen receptors prevent antigen escape by malignant B cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib180","unstructured":"Zarour, H. M., DeLeo, A., Finn, O. J., & Storkus, W. J. (2003). Categories of tumor antigens. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK12961."},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib181","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomarker Research"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.001_bib182","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib183","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and safety of CD28- or 4-1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Molecular Therapy Oncolytics"},{"key":"10.1016\/bs.apcsb.2023.12.001_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.001_bib185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell\u2013mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Molecular Therapy"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Immunology for Engineers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:07:58Z","timestamp":1753816078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162323001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443193507"],"references-count":185,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2023.12.001","relation":{},"ISSN":["1876-1623"],"issn-type":[{"type":"print","value":"1876-1623"}],"subject":[],"published":{"date-parts":[[2024]]}}}